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Abstract
Background: The ovarian cellular fibrous tumor with mitotic figure >4 per 10 high power field without
moderate to severe atypia is defined as mitotically active cellular fibroma according to the 2014 World Health
Organization classification. As this category is new and rare now, we described here a case of MACF and
reviewed the literature.
Case: We present a case of mitotically active cellular fibroma of the ovary with 10-year history that was
treated with laparoscopic surgery.
Methods: We reviewed the relevant literature using PubMed search system and analyzed the previous cases.
Results: To date, only 5 cases of mitotically active cellular fibroma have been reported. Our patient is the first
case of mitotically active cellular fibroma of the ovary treated with laparoscopic surgery.
Conclusion: MACF of the ovary is a newly defined category and few cases have been reported, while
prognostic factors have also not yet been fully characterized. Long-term clinical follow-up is necessary.
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Background
The ovarian cellular fibrous tumors with mitotic figures
>4 per 10 high-power fields (HPF) had been defined as
fibrosarcoma [1]. In 2014 World Health Organization
(WHO) histological classification, mitotic activity of >4
per 10 HPF in an ovarian cellular fibromatous neoplasm
in the absence of moderate to severe atypia is defined as
mitotically active cellular fibroma (MACF). As this cat-
egory is new and rare now, we described here a case of
MACF and reviewed systematically the literature for the
appropriate treatment.
Materials and methods
We treated a case of MACF, a new diagnostic category,
with a long term history. And we searched previous cases
using PubMed search system from 1966 to July 2015 with
the terms “mitotically active cellular fibroma”, “ovary”,
and “fibrosarcoma”. Then we analyzed and clarified that




A 36-year-old woman (gravida 3, para 3) consulted a
doctor for further examination of an ovarian tumor. She
had been diagnosed with a right-sided 6-cm ovarian
tumor 10 years previously, since her first pregnancy at
another hospital. Pelvic examination showed an adnexal
hard mass without tenderness on the right side. Vaginal
echography and pelvic computed tomography (CT)
showed a 6-cm ovarian solid tumor. Magnetic resonance
imaging (MRI) revealed a 61-mm solid tumor with het-
erogeneous low signal intensity in the pelvis. As such, a
benign tumor such as a fibroma/fibrothecoma or malig-
nant tumor such as a germ cell tumor or lymphoma
was suspected (Fig. 1). Serum levels of tumor markers
were negative for carcinoembryonic antigen (CEA),
CA125, CA19–9, squamous cell carcinoma (SCC),
human chorionic gonadotropin (HCG) and alpha feto-
protein (AFP). Laparoscopic surgery was performed to
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confirm diagnosis and direct treatment after 8 months
from the third delivery. Laparoscopic observation re-
vealed that the tumor in the Douglas pouch pro-
truded from the right ovary without adhesion
(Fig. 2). Subsequently, right salpingo-oophorectomy
was performed. The tumor was cut into small pieces in
the bag, which was then extracted from the laparoscopic
wound at the umbilicus without scattering in the ab-
dominal cavity. The sectioned surface of the tumor was
solid, light-yellow and without hemorrhagic necrosis
Fig. 1 MRI appearance of the tumor. Axial T2-weighted MR image showed a well-circumscribed mass (white arrows) including cystic
component (arrowhead) adjacent to the right ovary (black arrow) as having inhomogeneous low signal intensity. Small amount of ascites
was noted (*)
Fig. 2 Laparoscopic findings of the tumor. The tumor (white arrows) in the Douglas pouch protruded from right ovary (black arrow)
without adhesion
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(Fig. 3). Intraoperative cytology of ascitic fluid was nega-
tive, and intraoperative diagnosis of a frozen section re-
vealed benign fibrous tumor as atypical cells were not
observed.
In paraffin sections, the tumor cells were spindle shaped
and arranged in intersecting bundles (Fig. 4). They had ill-
defined cytoplasmic borders and spindled to ovoid hyper-
chromatic nuclei with a moderate mitotic rate (10 per 10
HPF) but without significant nuclear atypia (Fig. 5). The
cystic lesion was unclear. On immunohistochemistry,
vimentin, progesterone receptor (PR), CD10, CD56 and
Wilms tumor gene (WT-1) were positive, alpha-inhibin
was focally positive, and pan cytokeratin (AE1/AE3), estro-
gen receptor (ER), calretinin and epithelial membrane anti-
gen (EMA) were negative. Ki-67 index was 8.7 %.
Pathologic findings and the case’s long-term clinical history
led to the diagnosis of MACF of the ovary. She had a good
clinical course after surgery for 6 months.
Fig. 3 Macroscopic appearance of resected right oophorosalpinx. The sectioned surface of the tumor was solid and light-yellow without hemorrhagic
necrosis. (right ovary: black arrow)
Fig. 4 Macroscopic appearance of the tumor. The cells are spindle shaped and arranged in intersecting bandles. (bar = 200 μm)
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Review the literature
In connection with ovarian tumor, five cases were found
by a PubMed search system and shown in Table 1 [2–6].
Laparotomy was selected in all cases. Long-term local
recurrence has also been seen in one case but all
cases were alive at time of publication. However,
there was no specific tumor marker or immunochem-
ical staining.
Discussion
In the 2003 WHO histological classification, ovarian cellu-
lar fibrous tumors with mitotic figures 3 or less per 10
HPF and no severe nuclear atypia were defined as cel-
lular fibroma, while the fibrous tumors with mitotic
figures >4 per 10 HPF and severe nuclear atypia were
defined as fibrosarcoma. However, ovarian tumors with
mitotic figures >4 per 10 HPF but no severe nuclear
atypia were not categorized. These kinds of tumors
were mostly diagnosed as ovarian fibrosarcoma. How-
ever, the clinicopathologic characteristic of this tumor
is that it is significantly different from the malignant
behaviors of ovarian fibrosarcoma. In 2006, Irving et
al. first defined these kind of ovarian tumors as ‘MACF’
[7]. In the 2014 WHO histological classification, a new
definition was described: “mitotic activity of 4 per 10
HPFs in an ovarian cellular fibromatous neoplasm in
the absence of moderate to severe atypia does not sig-
nify a fibrosarcoma. In such cases, a diagnosis of
MACF is made.”
To date, only five cases of MACF of the ovary have
been reported in the literature. All cases were alive at
time of publication. However, there were no specific
diagnostic or prognostic factors.
Our patient is the first case of MACF of the ovary
treated with laparoscopic surgery. Ovarian benign fi-
brous tumors such as fibroma/fibrothecomas are often
misdiagnosed as uterine myomas and malignant ovarian
tumors preoperatively. However, laparoscopic surgery
has been used for the management of ovarian fibroma/
fibrothecomas [8, 9] and uterine myomas [10]. Histo-
logical diagnosis should be very important and include
intraoperative consultation. Even if many mitoses are
observed, it is imperative that we do not misdiagnose
fibrosarcoma, in order to avoid excessive treatment. In
our case, the tumor was benign both historically and
histologically.
Conclusions
We report a case of MACF with a long term history
treated by laparoscopic surgery. MACF of the ovary is a
newly defined category and few cases have been re-
ported, while prognostic factors have also not yet been
fully characterized. Treatment is still not well estab-
lished therefore long-term clinical follow-up including
image processing, such as echography, CT, MRI etc., is
necessary.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Fig. 5 Macroscopic appearance of the tumor. The cells having spindled to ovoid shaped nuclei with moderate mitotic rate (mitoses: white arrows) but
without significant nuclear atypia. (bar = 50 μm)
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ND, not described; CEA, carcinoembryonic antigen; (-), within normal range; AFP, α-feto protein; HCG, human chorionic gonadotropin; SCC, squamous cell carcinoma; TAH, total abdominal hysterectomy; BSO, bilateral
salpingo-oophorectomy; OMT, omentectomy; LD, lymphadenectomy; SMA, smooth muscle actin; HHF35, anti-muscle-specific actin (clone; HHF35); PR, progresterone receptor; ER, estrogen receptor; CK, cytokeratin; WT,














HPF: high-power fields; WHO: World Health Organization;
MACF: mitotically active cellular fibroma; CT: computed tomography;
MRI: magnetic resonance imaging; CEA: carcinoembryonic antigen;
SCC: squamous cell carcinoma; HCG: human chorionic gonadotropin;
AFP: alpha fetoprotein; PR: progesterone receptor; WT-1: Wilms tumor
gene; AE1/AE3: pan cytokeratin; ER: estrogen receptor; EMA: epithelial
membrane antigen.
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